{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:23:17Z","timestamp":1787844197597,"version":"build-2784847793"},"reference-count":106,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>While understanding the pathophysiology of migraine has led to CGRP-based treatments, other potential targets have also been implicated in migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To catalog new promising targets for the treatment of migraine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      We completed a literature review focusing on 5HT\n                      <jats:sub>1F<\/jats:sub>\n                      , PACAP, melatonin, and orexins.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The 5HT\n                      <jats:sub>1F<\/jats:sub>\n                      receptor agonist lasmiditan, following two positive randomized placebo-controlled trials, was FDA-approved for the acute treatment of migraine. PACAP-38 has shown analogous evidence to what was obtained for CGRP with its localization in key structures, provocation tests, and positive studies when antagonizing its receptor in animal models, although a PAC-1 receptor monoclonal antibody study was negative. Melatonin has undergone several randomized controlled trials showing a positive trend. Filorexant is the only dual orexin receptor antagonist, which was tested in humans with negative results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Further and ongoing studies will determine the utility of these new therapies with lasmiditan and melatonin having demonstrated efficacy for the treatment of migraine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0028-3886.315989","type":"journal-article","created":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T04:19:32Z","timestamp":1621138772000},"page":"S98-S104","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Emerging Targets for Migraine Treatment"],"prefix":"10.4103","volume":"69","author":[{"given":"David","family":"Moreno-Ajona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"Villar-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter James","family":"Goadsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20240907","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10194-012-0460-7","article-title":"Cost of healthcare for patients with migraine in five European countries: Results from the International Burden of Migraine Study (IBMS)","volume":"13","author":"Bloudek","year":"2012","journal-title":"J Headache Pain"},{"key":"R3-13-20240907","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: A disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol Rev"},{"key":"R4-13-20240907","first-page":"394","article-title":"Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90","volume":"34","author":"Goadsby","year":"1994","journal-title":"Headache"},{"key":"R5-13-20240907","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/WCO.0000000000000806","article-title":"Gepants, calcitonin-gene-related peptide receptor antagonists: What could be their role in migraine treatment?","volume":"33","author":"Moreno-Ajona","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"R6-13-20240907","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/0333102418821662","article-title":"CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications","volume":"39","author":"Dodick","year":"2019","journal-title":"Cephalalgia"},{"key":"R7-13-20240907","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N Engl J Med"},{"key":"R8-13-20240907","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol"},{"key":"R9-13-20240907","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1177\/0333102418788347","article-title":"Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study","volume":"38","author":"Ashina","year":"2018","journal-title":"Cephalalgia"},{"key":"R10-13-20240907","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: A Phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia"},{"key":"R11-13-20240907","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1177\/0333102419835459","article-title":"Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study","volume":"39","author":"Goadsby","year":"2019","journal-title":"Cephalalgia"},{"key":"R12-13-20240907","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the preventive treatment of chronic migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"New Engl J Med"},{"key":"R13-13-20240907","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: A randomized clinical trial","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"key":"R14-13-20240907","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): A randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"key":"R15-13-20240907","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1212\/WNL.92.15_supplement.S38.004","article-title":"Long-term efficacy and safety of fremanezumab in migraine: Results of a 1-year study","volume":"92","author":"Goadsby","year":"2019","journal-title":"Neurology"},{"key":"R16-13-20240907","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12883-018-1193-2","article-title":"A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine","volume":"18","author":"Camporeale","year":"2018","journal-title":"BMC Neurol"},{"key":"R17-13-20240907","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"R18-13-20240907","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"key":"R19-13-20240907","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"key":"R20-13-20240907","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1177\/0333102419847957","article-title":"Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure","volume":"39","author":"Ruff","year":"2019","journal-title":"Cephalalgia"},{"key":"R22-13-20240907","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1177\/0333102419858355","article-title":"Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial","volume":"39","author":"Dodick","year":"2019","journal-title":"Cephalalgia"},{"key":"R23-13-20240907","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"key":"R24-13-20240907","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"key":"R25-13-20240907","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1046\/j.1468-2982.1995.1504272.x","article-title":"Neuropeptides in the cerebral circulation: Relevance to headache","volume":"15","author":"Edvinsson","year":"1995","journal-title":"Cephalalgia"},{"key":"R26-13-20240907","first-page":"269","article-title":"Pituitary adenylate cyclase-activating polypeptide and its receptors: From structure to functions","volume":"52","author":"Vaudry","year":"2000","journal-title":"Pharmacol Rev"},{"key":"R27-13-20240907","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000229194","article-title":"Biochemical investigations in headache: Increase in the hydroxyindoleacetic acid excretion during migraine attacks","volume":"19","author":"Sicuteri","year":"1961","journal-title":"Int Arch Allergy Immunol"},{"key":"R28-13-20240907","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/brain\/88.5.997","article-title":"Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects","volume":"88","author":"Curran","year":"1965","journal-title":"Brain"},{"key":"R29-13-20240907","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/archneur.1967.00470230096013","article-title":"Plasma serotonin in migraine and stress","volume":"16","author":"Anthony","year":"1967","journal-title":"Arch Neurol"},{"key":"R30-13-20240907","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1212\/WNL.10.2.107","article-title":"Effect of serotonin in migraine patients","volume":"10","author":"Kimball","year":"1960","journal-title":"Neurology"},{"key":"R31-13-20240907","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/head.1967.7.3.93","article-title":"The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome","volume":"7","author":"Lance","year":"1967","journal-title":"Headache"},{"key":"R32-13-20240907","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0014-2999(99)00067-9","article-title":"Both 5-HT1B and 5-HT1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis","volume":"369","author":"Mitsikostas","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"R33-13-20240907","first-page":"152","article-title":"Lasmiditan inhibits trigeminovascular nociceptive transmission","volume":"36","author":"Vila-Pueyo","year":"2016","journal-title":"Cephalalgia"},{"key":"R34-13-20240907","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0306-4522(03)00570-0","article-title":"Evidence for 5-HT1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input","volume":"122","author":"Goadsby","year":"2003","journal-title":"Neuroscience"},{"key":"R35-13-20240907","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1365-2125.1999.00851.x","article-title":"Vasoconstriction in human isolated middle meningeal arteries: Determining the contribution of 5-HT(1B)- and 5-HT(1F)-receptor activation","volume":"47","author":"Razzaque","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"R36-13-20240907","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0301-0082(00)00010-1","article-title":"The pharmacology of headache","volume":"62","author":"Goadsby","year":"2000","journal-title":"Prog Neurobiol"},{"key":"R37-13-20240907","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1046\/j.1468-2982.2003.00525.x","article-title":"5-HT1F receptor agonists in acute migraine treatment: A hypothesis","volume":"23","author":"Ramadan","year":"2003","journal-title":"Cephalalgia"},{"key":"R38-13-20240907","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0333102410370873","article-title":"Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan","volume":"30","author":"Nelson","year":"2010","journal-title":"Cephalalgia"},{"key":"R39-13-20240907","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40265-019-01225-7","article-title":"Lasmiditan: First approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"R40-13-20240907","first-page":"362","article-title":"Lasmiditan inhibits CGRP release in the mouse trigeminovascular system","volume":"37","author":"Labastida-Ram\u00edrez","year":"2017","journal-title":"Cephalagia"},{"key":"R41-13-20240907","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1111\/bph.14832","article-title":"Characterization of binding, functional activity, and contractile responses of the selective 5-HT","volume":"176","author":"Rubio-Beltr\u00e1n","year":"2019","journal-title":"Br J Pharmacol"},{"key":"R42-13-20240907","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study","volume":"91","author":"Kuca","year":"2018","journal-title":"Neurology"},{"key":"R43-13-20240907","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine","volume":"142","author":"Goadsby","year":"2019","journal-title":"Brain"},{"key":"R44-13-20240907","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0333102419889350","article-title":"Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans","volume":"40","author":"Knievel","year":"2020","journal-title":"Cephalalgia"},{"key":"R45-13-20240907","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1177\/0333102419864132","article-title":"Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)","volume":"39","author":"Brandes","year":"2019","journal-title":"Cephalalgia"},{"key":"R46-13-20240907","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s10194-020-01138-x","article-title":"Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: A systematic review and meta-analysis","volume":"21","author":"Hou","year":"2020","journal-title":"J Headache Pain"},{"key":"R47-13-20240907","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1111\/j.1460-9568.2006.05036.x","article-title":"Animal models of migraine: Looking at the component parts of a complex disorder","volume":"24","author":"Bergerot","year":"2006","journal-title":"Eur J Neurosci"},{"key":"R48-13-20240907","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/brain\/awt369","article-title":"Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38","volume":"137","author":"Amin","year":"2014","journal-title":"Brain"},{"key":"R49-13-20240907","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/0333102410375624","article-title":"Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery","volume":"31","author":"Chan","year":"2011","journal-title":"Cephalalgia"},{"key":"R50-13-20240907","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/0006-291X(90)92140-U","article-title":"Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38)","volume":"170","author":"Miyata","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"R51-13-20240907","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.nurt.2010.02.003","article-title":"The PACAP receptor: A novel target for migraine treatment","volume":"7","author":"Schytz","year":"2010","journal-title":"Neurotherapeutics"},{"key":"R52-13-20240907","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s10194-018-0852-4","article-title":"PACAP and its role in primary headaches","volume":"19","author":"Edvinsson","year":"2018","journal-title":"J Headache Pain"},{"key":"R53-13-20240907","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1476-5381.2012.01871.x","article-title":"Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1","volume":"166","author":"Harmar","year":"2012","journal-title":"Br J Pharmacol"},{"key":"R54-13-20240907","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0306-4522(93)90018-B","article-title":"Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: Immunocytochemical and immunochemical evidence","volume":"57","author":"Moller","year":"1993","journal-title":"Neuroscience"},{"key":"R55-13-20240907","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/0333102419893962","article-title":"Cellular distribution of PACAP-38 and PACAP receptors in the rat brain: Relation to migraine activated regions","volume":"40","author":"Warfvinge","year":"2020","journal-title":"Cephalalgia"},{"key":"R56-13-20240907","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.brainres.2014.11.031","article-title":"Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood\u2013brain barrier","volume":"1600","author":"Eftekhari","year":"2015","journal-title":"Brain Res"},{"key":"R57-13-20240907","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/acn3.113","article-title":"Pituitary adenylate cyclase activating polypeptide and migraine","volume":"1","author":"Zagami","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"R58-13-20240907","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s10194-016-0664-3","article-title":"Expression of messenger molecules and receptors in rat and human sphenopalatine ganglion indicating therapeutic targets","volume":"17","author":"Steinberg","year":"2016","journal-title":"J Headache Pain"},{"key":"R59-13-20240907","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/0333102416644435","article-title":"PACAP38 dose-response pilot study in migraine patients","volume":"37","author":"Vollesen","year":"2017","journal-title":"Cephalalgia"},{"key":"R60-13-20240907","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/brain\/awn307","article-title":"PACAP38 induces migraine-like attacks in patients with migraine without aura","volume":"132","author":"Schytz","year":"2009","journal-title":"Brain"},{"key":"R61-13-20240907","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1177\/0333102413483931","article-title":"Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients","volume":"33","author":"Tuka","year":"2013","journal-title":"Cephalalgia"},{"key":"R62-13-20240907","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0333102419864507","article-title":"PACAP27 induces migraine-like attacks in migraine patients","volume":"40","author":"Ghanizada","year":"2020","journal-title":"Cephalalgia"},{"key":"R63-13-20240907","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/0306-4522(93)90019-C","article-title":"Pituitary adenylate cyclase activating peptide produces a marked and long-lasting depression of a C-fibre-evoked flexion reflex","volume":"57","author":"Zhang","year":"1993","journal-title":"Neuroscience"},{"key":"R64-13-20240907","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1097\/j.pain.0000000000001858","article-title":"PAC1 receptor blockade reduces central nociceptive activity: New approach for primary headache?","volume":"161","author":"Hoffmann","year":"2020","journal-title":"Pain"},{"key":"R65-13-20240907","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1080\/13543784.2020.1811966","article-title":"Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: A brief review","volume":"29","author":"Rustichelli","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"R66-13-20240907","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1124\/jpet.118.253443","article-title":"Pharmacologic characterization of ALD1910, a potent humanized monoclonal antibody against the pituitary adenylate cyclase-activating peptide","volume":"369","author":"Moldovan Loomis","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"R67-13-20240907","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1212\/01.WNL.0000052998.58526.A9","article-title":"Premonitory symptoms in migraine: An electronic diary study","volume":"60","author":"Giffin","year":"2003","journal-title":"Neurology"},{"key":"R69-13-20240907","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1186\/1129-2377-15-84","article-title":"The origin of nausea in migraine-A PET study","volume":"15","author":"Maniyar","year":"2014","journal-title":"J Headache Pain"},{"key":"R70-13-20240907","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/0748730404269008","article-title":"It's all in the timing: Many clocks, many outputs","volume":"19","author":"Panda","year":"2004","journal-title":"J Biol Rhythms"},{"key":"R71-13-20240907","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41582-018-0098-4","article-title":"Biological insights from the premonitory symptoms of migraine","volume":"14","author":"Karsan","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"R72-13-20240907","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0304-3940(76)90070-7","article-title":"Cells of origin of hypothalamo-spinal projections in the rat","volume":"3","author":"Hancock","year":"1976","journal-title":"Neurosci Lett"},{"key":"R73-13-20240907","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/j.1526-4610.2007.00776.x","article-title":"Hypothalamic activation in spontaneous migraine attacks","volume":"47","author":"Denuelle","year":"2007","journal-title":"Headache"},{"key":"R74-13-20240907","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/brain\/awt320","article-title":"Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks","volume":"137","author":"Maniyar","year":"2014","journal-title":"Brain"},{"key":"R75-13-20240907","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fneur.2020.00140","article-title":"Imaging the premonitory phase of migraine","volume":"11","author":"Karsan","year":"2020","journal-title":"Front Neurol"},{"key":"R76-13-20240907","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1177\/0269881119855343","article-title":"British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update","volume":"33","author":"Wilson","year":"2019","journal-title":"J Psychopharmacol"},{"key":"R77-13-20240907","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1526-4610.2005.05159.x","article-title":"Headache and sleep: Examination of sleep patterns and complaints in a large clinical sample of migraineurs","volume":"45","author":"Kelman","year":"2005","journal-title":"Headache"},{"key":"R78-13-20240907","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1468-2982.2001.00141.x","article-title":"Polysomnographic findings in nights preceding a migraine attack","volume":"21","author":"Goder","year":"2001","journal-title":"Cephalalgia"},{"key":"R79-13-20240907","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1056\/NEJM199701163360306","article-title":"Melatonin in humans","volume":"336","author":"Brzezinski","year":"1997","journal-title":"N Engl J Med"},{"key":"R80-13-20240907","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/head.13828","article-title":"Endogenous melatonin levels and therapeutic use of exogenous melatonin in migraine: Systematic review and meta-analysis","volume":"60","author":"Liampas","year":"2020","journal-title":"Headache"},{"key":"R81-13-20240907","doi-asserted-by":"crossref","first-page":"e12663","DOI":"10.1111\/jpi.12663","article-title":"The association between melatonin and episodic migraine: A pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy","volume":"69","author":"Tseng","year":"2020","journal-title":"J Pineal Res"},{"key":"R82-13-20240907","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1212\/WNL.0b013e3181f9618c","article-title":"Prophylaxis of migraine with melatonin: A randomized controlled trial","volume":"75","author":"Alstadhaug","year":"2010","journal-title":"Neurology"},{"key":"R83-13-20240907","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/jnnp-2016-313458","article-title":"Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention","volume":"87","author":"Goncalves","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R84-13-20240907","first-page":"385","article-title":"Use of melatonin versus valproic acid in prophylaxis of migraine patients: A double-blind randomized clinical trial","volume":"35","author":"Ebrahimi-Monfared","year":"2017","journal-title":"Restor Neurol Neurosci"},{"key":"R85-13-20240907","first-page":"47","article-title":"A randomized clinical trial comparing the efficacy of melatonin and amitriptyline in migraine prophylaxis of children","volume":"12","author":"Fallah","year":"2018","journal-title":"Iran J Child Neurol"},{"key":"R86-13-20240907","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/jamaneurol.2017.0285","article-title":"Home-based trials in adolescent migraine: A randomized clinical trial","volume":"74","author":"Gelfand","year":"2017","journal-title":"JAMA Neurol"},{"key":"R87-13-20240907","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1111\/head.13934","article-title":"Melatonin for acute treatment of migraine in children and adolescents: A pilot randomized trial","volume":"60","author":"Gelfand","year":"2020","journal-title":"Headache"},{"key":"R88-13-20240907","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1468-2982.2003.00343.x","article-title":"Increased frequency of migraine in narcoleptic patients: A confirmatory study","volume":"23","author":"Dahmen","year":"2003","journal-title":"Cephalalgia"},{"key":"R89-13-20240907","doi-asserted-by":"crossref","first-page":"e0189231","DOI":"10.1371\/journal.pone.0189231","article-title":"Migraine and risk of narcolepsy in children: A nationwide longitudinal study","volume":"12","author":"Yang","year":"2017","journal-title":"PLoS One"},{"key":"R90-13-20240907","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","article-title":"Reduced number of hypocretin neurons in human narcolepsy","volume":"27","author":"Thannickal","year":"2000","journal-title":"Neuron"},{"key":"R91-13-20240907","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/79690","article-title":"A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains","volume":"6","author":"Peyron","year":"2000","journal-title":"Nat Med"},{"key":"R92-13-20240907","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R93-13-20240907","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1523\/JNEUROSCI.19-08-03171.1999","article-title":"Hypothalamic hypocretin (orexin): Robust innervation of the spinal cord","volume":"19","author":"van den Pol","year":"1999","journal-title":"J Neurosci"},{"key":"R94-13-20240907","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","article-title":"Neurons containing hypocretin (orexin) project to multiple neuronal systems","volume":"18","author":"Peyron","year":"1998","journal-title":"J Neurosci"},{"key":"R95-13-20240907","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1526-4610.2007.00842.x","article-title":"The hypothalamic orexinergic system: Pain and primary headaches","volume":"47","author":"Holland","year":"2007","journal-title":"Headache"},{"key":"R96-13-20240907","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/00001756-200104170-00026","article-title":"Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation","volume":"12","author":"Fujiki","year":"2001","journal-title":"Neuroreport"},{"key":"R97-13-20240907","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"R98-13-20240907","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/sj.bjp.0704851","article-title":"Analgesic effect of intrathecally administered orexin-A in the rat formalin test and in the rat hot plate test","volume":"137","author":"Yamamoto","year":"2002","journal-title":"Br J Pharmacol"},{"key":"R99-13-20240907","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0304-3959(00)00470-X","article-title":"Orexin-A, an hypothalamic peptide with analgesic properties","volume":"92","author":"Bingham","year":"2001","journal-title":"Pain"},{"key":"R100-13-20240907","first-page":"119","article-title":"Analgesic effect of intrathecal administration of orexin on neuropathic pain in rats","volume":"18","author":"Suyama","year":"2004","journal-title":"In Vivo"},{"key":"R101-13-20240907","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00001756-200501190-00002","article-title":"Persistent pain and stress activate pain-inhibitory orexin pathways","volume":"16","author":"Watanabe","year":"2005","journal-title":"Neuroreport"},{"key":"R102-13-20240907","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.pain.2004.02.005","article-title":"Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area","volume":"109","author":"Bartsch","year":"2004","journal-title":"Pain"},{"key":"R103-13-20240907","first-page":"S6","article-title":"Antinociceptive effects of orexin A in the ventrolateral periaquaductal gray are blocked by 5-HT1B\/1D receptor antagonism [Abstract]","volume":"48","author":"Holland","year":"2008","journal-title":"Headache"},{"key":"R104-13-20240907","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1111\/j.1460-9568.2006.05168.x","article-title":"Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat","volume":"24","author":"Holland","year":"2006","journal-title":"Eur J Neurosci"},{"key":"R105-13-20240907","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.nbd.2014.10.022","article-title":"Evidence for orexinergic mechanisms in migraine","volume":"74","author":"Hoffmann","year":"2015","journal-title":"Neurobiol Dis"},{"key":"R106-13-20240907","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neuroscience.2014.03.043","article-title":"Dual orexin receptor antagonist 12 inhibits expression of proteins in neurons and glia implicated in peripheral and central sensitization","volume":"269","author":"Cady","year":"2014","journal-title":"Neuroscience"},{"key":"R107-13-20240907","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1468-2982.2008.01566.x","article-title":"Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: Findings from cerebrospinal fluid","volume":"28","author":"Sarchielli","year":"2008","journal-title":"Cephalalgia"},{"key":"R108-13-20240907","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/0333102414544979","article-title":"Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis","volume":"35","author":"Chabi","year":"2015","journal-title":"Cephalalgia"},{"key":"R109-13-20240907","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrn.2017.62","article-title":"Non-motor features of Parkinson disease","volume":"18","author":"Schapira AHV","year":"2017","journal-title":"Nat Rev Neurosci"}],"container-title":["Neurology India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.315989","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:13:59Z","timestamp":1787843639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0028-3886.315989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":106,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/0028-3886.315989","relation":{},"ISSN":["0028-3886"],"issn-type":[{"value":"0028-3886","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}